Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session

80O - Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study


31 Mar 2022


Proffered Paper session


Tumour Site

Non-Small Cell Lung Cancer


Enriqueta Felip


Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857


E. Felip1, N.K. Altorki2, C. Zhou3, E. Vallieres4, I.O. Vynnychenko5, A. Akopov6, A. Martinez-Marti1, A. Chella7, I. Bondarenko8, G. Ursol9, E. Levchenko10, N. Kislov11, R. Liersch12, R. Belleli13, V.A. McNally14, E. Bennett15, B.J. Gitlitz16, H. Wakelee17

Author affiliations

  • 1 Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona/ES
  • 2 New York-Presbyterian Hospital, Weill Cornell Medicine, 10065 - New York/US
  • 3 Shanghai Pulmonary Hospital, Shanghai/CN
  • 4 Swedish Cancer Institute, Seattle/US
  • 5 Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy/UA
  • 6 Pavlov State Medical University, 197022 - Saint-Petersburg/RU
  • 7 Pneumology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa/IT
  • 8 Dnipro State Medical University, Dnipro/UA
  • 9 Acinus, 25006 - Kropyvnytskyi/UA
  • 10 N.N. Petrov National Medical Research Center of Oncology, St. Petersburg/RU
  • 11 Regional Clinical Oncology Hospital, Yaroslavl/RU
  • 12 Clemenshospital Münster, Münster/DE
  • 13 F. Hoffmann-La Roche Ltd, Basel/CH
  • 14 Roche Products Ltd, AL7 1TW - Welwyn Garden City/GB
  • 15 Genentech Inc, South San Francisco/US
  • 16 Genentech Inc, 94080 - South San Francisco/US
  • 17 Stanford University School of Medicine/Stanford Cancer Institute, Stanford/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 80O


IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC ≥1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC ≥50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC ≥50% stage II-IIIA NSCLC pts.


IMpower010 (NCT02486718) study design and primary DFS analysis details have been reported (Felip Lancet 2021). DFS in PD-L1 TC ≥50% (VENTANA SP263 assay) stage II-IIIA (UICC/AJCC v7) pts was a prespecified secondary endpoint; additional subgroup data reported are exploratory.


Baseline characteristics were generally balanced for atezo- vs BSC-arm pts with PD-L1 TC ≥50% stage II-IIIA NSCLC (male, 77% vs 68%; stage III, 46% vs 50%; nonsquamous, 59% vs 61%). Median follow-up was 34.2 mo (21 Jan 2021 cutoff). See the table for DFS subgroup data. Safety in PD-L1 TC ≥50% stage II-IIIA pts was consistent with that of the overall study population and known safety profile of atezo. Initial disease relapse in this population was locoregional-only in 15/25 atezo-arm pts (60%) vs 17/50 BSC-arm pts (34%) and distant-only in 6/25 (24%) vs 21/50 (42%); initial CNS-only relapse was seen in 1/25 (4%) vs 7/50 (14%). 19 relapsing atezo-arm pts (76%) vs 30 BSC-arm pts (60%) had subsequent systemic therapy (mostly chemo, 60% vs 32%; immunotherapy, 16% vs 38%).


IMpower010 pts with PD-L1 TC ≥50% stage II-IIIA NSCLC derived DFS benefit with atezo vs BSC at the interim DFS analysis. Data were consistent across most subgroups, albeit with limited pt numbers in this post hoc analysis. Numerically, more distant and CNS relapses were seen with BSC. The tolerability profile of atezo was in line with the overall population, demonstrating a positive benefit-risk profile. Table: 80O

Interim DFS: PD-L1 TC ≥50% stage II-IIIA

Pts, n Unstratified DFS HR (95% CI)
Atezo BSC
Age <65 y ≥65 y 71 44 70 44 0.49 (0.27, 0.89) 0.36 (0.17, 0.75)
Sex Male Female 89 26 78 36 0.50 (0.28, 0.89) 0.34 (0.15, 0.76)
Histology Squamous Nonsquamous 47 68 45 69 0.60 (0.29, 1.26) 0.36 (0.20, 0.65)
Stage II IIIA 62 53 57 57 0.51 (0.26, 1.00) 0.38 (0.20, 0.72)
Regional LN N0 N1 N2 30 43 42 21 52 41 1.09 (0.39, 3.07) 0.29 (0.12, 0.72) 0.35 (0.18, 0.68)
Smoking status Current/former Never 99 16 99 15 0.40 (0.24, 0.68) 0.46 (0.17, 1.25)
EGFR/ALK mutation Detected Undetected Unknown 9 52 54 11 54 49 0.26 (0.06, 1.02) 0.41 (0.20, 0.84) 0.45 (0.23, 0.91)

DFS event/pts: atezo, 28/115 (24%); BSC, 52/114 (46%).

Clinical trial identification


Editorial acknowledgement

Medical writing assistance for this abstract was provided by Ashley J Pratt, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.


F. Hoffmann-La Roche, Ltd.


E. Felip: Other, Personal, Invited Speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Roche, Janssen, MSD, Merck Serono, Pfizer, PeerVoice, Springer, Touch Medical; Other, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Roche, GlaxoSmithKline, Medical Trends, Peptomyc, Puma Biotechnology, Regeneron, Sanofi, Takeda, Janssen, MSD, Merck Serono, Pfizer; Other, Institutional, Research Grant, Research Funding: Oncology Innovation, Merck Healthcare KGAa, Fundacion Merck Salud; Other, Personal, Member of the Board of Directors, Independent Member of the Board: GRIFOLS. N.K. Altorki: Financial Interests, Institutional, Research Grant: AstraZeneca, Janssen, NCI, DoD. C. Zhou: Financial Interests, Personal, Invited Speaker: Roche China, Lily China, BI, Sanofi, C-Stone, Qilu, Hengrui, Innovent Biologics, LUYE Pharma, TopAlliance Bioscience Inc, Amoy Diagnostics. A. Martinez-Marti: Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Roche, Merck, Pfizer, MSD Oncology, AstraZeneca; Financial Interests, Personal, Other, Personal Fees and Travel Expenses outside the submitted work: Bristol Myers Squibb, Roche, MSD, Pfizer, Boehringer Ingelheim, MSD Oncology, AstraZeneca. N. Kislov: Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca, Eisai, EMD Serono, Exelixis, MSD, Genentech/Roche, GlaxoSmithKlein, Ipsen Novartis, Pfizer, Nektar, Lilly; Financial Interests, Personal, Invited Speaker: Biocad, Ipsen, Roche. R. Belleli: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. V.A. McNally: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. E. Bennett: Financial Interests, Personal, Full or part-time Employment: Genentech/Roche; Financial Interests, Personal, Stocks/Shares: Roche. B.J. Gitlitz: Financial Interests, Personal, Full or part-time Employment: Genentech/Roche; Financial Interests, Personal, Stocks/Shares: Roche. H. Wakelee: Financial Interests, Institutional, Research Grant: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Helsinn, Merck, Novartis, Pharmacyclics, Seagen, Xcovery; Financial Interests, Personal, Advisory Role, Consulting: AstraZeneca, Blueprint, Mirati. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.